Submit your email to push it up the queue
Novartis International AG, commonly referred to as Novartis, is a leading global healthcare company headquartered in Switzerland (CH). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in pharmaceuticals and generics, Novartis focuses on innovative medicines, particularly in areas such as oncology, cardiology, and immunology. The company is renowned for its commitment to research and development, with notable achievements including the introduction of groundbreaking therapies that address unmet medical needs. With a robust portfolio of patented drugs and a significant market position, Novartis continues to be a pivotal player in the global healthcare landscape, dedicated to improving patient outcomes through science and innovation.
How does Novartis International AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Novartis International AG's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
As of the latest available data, Novartis International AG does not report specific carbon emissions figures, indicating a lack of recent emissions data. However, the company is part of a corporate family that includes Novartis AG, which may have relevant climate commitments and initiatives. Novartis International AG is currently a subsidiary of Novartis AG, which has set various climate-related targets and initiatives. These include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Novartis AG. The specific reduction targets and achievements of Novartis AG are not detailed in the provided information, but the company is actively engaged in climate action and sustainability efforts. While no absolute emissions data is available, Novartis AG's involvement in these initiatives suggests a commitment to reducing its carbon footprint and addressing climate change. The absence of specific emissions figures highlights the need for transparency and accountability in corporate climate reporting.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis International AG is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.